Ozempic is first GLP-1 drug FDA-approved for kidney disease Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of worsening kidney disease in people with type 2 diabetes
Summary Summary of Dietary Reference Values-version 4 (Overview on Dietary Reference Values for the EU Population as Derived by the EFSA Panel on Dietetic Products Nutrition and Allergies (NDA) (2017)
Risks of Rapid Dose Escalation Speeding up dose escalation may seem beneficial at first, especially when patients experience quick weight loss or improved glucose control with GLP-1 therapy
Sprouted green gram as a breakfast chaat is even more effective: raw sprouted moong provides maximum fibre, protein, and Vitamin C at approximately 30 kcal per 100 g fresh weight
Clinical Studies There were approximately 3800 patients with type 2 diabetes randomized in six double-blind, placebo-controlled clinical safety and efficacy studies conducted to evaluate the effects of sitagliptin on glycemic control
Differences in characteristics among 1,000 women with endometriosis based on extent of disease
